EL7.AI
StocksMedium•24 March 2026•
1 min read

WuXi Biologics and Rubicon Organics Report Full-Year 2025 Financial Results

Key Facts

1WuXi Biologics revenue increased 16.7% YoY to RMB 21.8 billion in 2025.
2WuXi Biologics net profit jumped 45.3% YoY with gross profit margin expanding to 46.0%.
3WuXi Biologics total backlog reached US$23.7 billion, with strong growth in bispecifics and ADCs.
4Rubicon Organics, a Canadian premium cannabis producer, announced its financial results for the 2025 fiscal year.

WuXi Biologics and Rubicon Organics Inc. have released their audited financial results for the 2025 fiscal year. WuXi Biologics delivered a record-breaking performance, with annual revenue climbing 16.7% year-over-year to RMB 21.8 billion. The company's net profit saw a significant surge of 45.3%, supported by a gross profit margin expansion to 46.0%. Furthermore, the total backlog for WuXi Biologics reached US$23.7 billion, driven by robust demand in the bispecific antibodies and ADC sectors. Meanwhile, Canadian premium cannabis producer Rubicon Organics also confirmed its fiscal 2025 performance, solidifying its market position. These results highlight a strong growth trajectory for WuXi Biologics, exceeding industry expectations in terms of profitability and operational scale.